IMUX250117P2500
- 1.45
- 0.000.00%
Immunic Newsroom
Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX
Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating
Immunic, Inc. to Participate in Investor Conference in December
Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.
Express News | Immunic, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Insider Buys Additional US$100k In Immunic Stock
Immunic Announces Publication of IMU-856 Data
Immunic Reports Positive Phase 1 Results for Celiac Disease Therapy Published in The Lancet | NASDAQ:IMUX
Express News | Immunic Announces Publication of Data From Phase 1/1B Clinical Trial of Imu-856 in the Peer Reviewed Journal, the Lancet Gastroenterology & Hepatology
Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript Summary
Immunic, Inc. Advances MS Trials Amid Financial Update
EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Immunic Analyst Ratings
Immunic CEO Details Progress Following Productive Third Quarter | NASDAQ:IMUX
Immunic | 10-Q: Q3 2024 Earnings Report
Immunic | 8-K: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update